Advertisement

Kinase Inhibitor Profiling Using Chemoproteomics

  • Markus SchirleEmail author
  • Eugene C. Petrella
  • Scott M. Brittain
  • David Schwalb
  • Edmund Harrington
  • Ivan Cornella-Taracido
  • John A. Tallarico
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 795)

Abstract

Quantitative chemoproteomics has recently emerged as an experimental approach to determine protein interaction profiles of small molecules in a given cell line or tissue. In contrast to standard biochemical and biophysical kinase assays, application of this method to kinase inhibitors determines compound binding to endogenously expressed kinases under conditions approximating the physiological situation with regard to the molecular state of the kinase and presence of required cofactors and regulatory proteins. Using a dose-dependent, competition-based experimental design in combination with quantitative mass spectrometry approaches, such as the use of tandem mass tags (TMT) for isobaric labeling described here, allows to rank-order interactions of inhibitors to kinase by binding affinity.

Key words

Chemoproteomics Quantitative proteomics Target identification Isobaric mass tags 

Notes

Acknowledgments

We thank Heather Contant and Lindsay Nolitt for expert technical assistance and John Damask and Ioannis Moutsatsos for their crucial role in building the data processing and analysis environment.

References

  1. 1.
    Fabian, M. A., Biggs, W. H., III, Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., Ford, J. M., Galvin, M., Gerlach, J. L., Grotzfeld, R. M., Herrgard, S., Insko, D. E., Insko, M. A., Lai, A. G., Lelias, J. M., Mehta, S. A., Milanov, Z. V., Velasco, A. M., Wodicka, L. M., Patel, H. K., Zarrinkar, P. P., and Lockhart, D. J. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat.Biotechnol. 23, 329–336.Google Scholar
  2. 2.
    Vesely, J., Havlicek, L., Strnad, M., Blow, J. J., Donella-Deana, A., Pinna, L., Letham, D. S., Kato, J., Detivaud, L., and Leclerc, S. (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur.J. Biochem. 224, 771–786.Google Scholar
  3. 3.
    Hall, S. E. (2006) Chemoproteomics-driven drug discovery: addressing high attrition rates. Drug Discovery Today 11, 495–502.Google Scholar
  4. 4.
    Rix, U. and Superti-Furga, G. (2009) Target profiling of small molecules by chemical proteomics. Nat. Chem. Biol. 5, 616–624.Google Scholar
  5. 5.
    Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035–1044.Google Scholar
  6. 6.
    Oppermann, F. S., Gnad, F., Olsen, J. V., Hornberger, R., Greff, Z., Keri, G., Mann, M., and Daub, H. (2009) Large-scale proteomics analysis of the human kinome. Mol.Cell Proteomics. 8, 1751–1764.Google Scholar
  7. 7.
    Graves, P. R., Kwiek, J. J., Fadden, P., Ray, R., Hardeman, K., Coley, A. M., Foley, M., and Haystead, T. A. (2002) Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol.Pharmacol. 62, 1364–1372.Google Scholar
  8. 8.
    Ong, S. E., Schenone, M., Margolin, A. A., Li, X. Y., Do, K., Doud, M. K., Mani, D. R., Kuai, L., Wang, X., Wood, J. L., Tolliday, N. J., Koehler, A. N., Marcaurelle, L. A., Golub, T. R., Gould, R. J., Schreiber, S. L., and Carr, S. A. (2009) Identifying the proteins to which small-­molecule probes and drugs bind in cells. Proc. Natl. Acad. Sci. USA 106,4617–4622.Google Scholar
  9. 9.
    Sharma, K., Weber, C., Bairlein, M., Greff, Z., Keri, G., Cox, J., Olsen, J. V., and Daub, H. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741–744.Google Scholar
  10. 10.
    Garcia-Echeverria, C., Kanazawa, T., Kawahara, E., Masuya, K., Matsuura, N., Miyake, T., Ohmori, O., and Umemura, I. (2004) Preparation of novel 2,4-di(phenylamino)pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. WO2004080980 A1 20040923.Google Scholar
  11. 11.
    Baenteli, R., Zenke, G., Cooke, N. G., Duthaler, R., Thoma, G., Von Matt, A., Honda, T., Matsuura, N., Nonomura, K., Ohmori, O., Umemura, I., Hinterding, K., and Papageorgiou, C. (2003) Pyrimidine derivatives. PCT Int. Appl. WO 2003078404 A1 20030925.Google Scholar
  12. 12.
    Duthaler, R., Gerspacher, M., Holzer, P., Streiff, M., Thoma, G., Waelchli, R., and Zerwes, HG. (2007) Preparation of 2,4-di(arylamino)-pyrimidine-5-carboxamides as JAK kinases inhibitors. PCT Int. Appl. WO 2008009458 A1 20080124.Google Scholar
  13. 13.
    Garcia-Echeverria, C., Kanazawa, T., Kawahara, E., Masuya, K., Matsuura, N., Miyake, T., Ohmori, O., Umemura, I., Steensma, R., Chopiuk, G., Jiang, J., Wan, Y., Zhang, Q., Gray, N. S., and Karanewsky, D. (2004) Preparation of 2,4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders. PCT Int. Appl. WO2005016894 A1 20050224.Google Scholar
  14. 14.
    Argade, A., Singh, R., Li, H., Carroll, D., and Catalano, S. (2004) 2,4-pyrimidinediamine compounds and uses as antiproliferative agents. PCT Int. Appl. WO 2005013996 A2 20050217.Google Scholar
  15. 15.
    Bantscheff, M., Boesche, M., Eberhard, D., Matthieson, T., Sweetman, G., and Kuster, B. (2008) Robust and sensitive iTRAQ quantification on an LTQ Orbitrap mass spectrometer. Mol.Cell Proteomics. 7, 1702–1713.Google Scholar
  16. 16.
    Jaffe, J. D., Keshishian, H., Chang, B., Addona, T. A., Gillette, M. A., and Carr, S. A. (2008) Accurate inclusion mass screening: a bridge from unbiased discovery to targeted assay development for biomarker verification. Mol.Cell Proteomics. 7, 1952–1962.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Markus Schirle
    • 1
    Email author
  • Eugene C. Petrella
    • 1
  • Scott M. Brittain
    • 1
  • David Schwalb
    • 1
  • Edmund Harrington
    • 1
  • Ivan Cornella-Taracido
    • 1
  • John A. Tallarico
    • 1
  1. 1.Novartis Institutes for Biomedical ResearchCambridgeUSA

Personalised recommendations